Found: 11
Select item for more details and to access through your institution.
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
- Published in:
- Liver International, 2018, v. 38, n. 9, p. 1571, doi. 10.1111/liv.13708
- By:
- Publication type:
- Article
Response to Cytoplasmic rods and rings in ribavirin and Cytoplasmic rods and rings in mycophenolic acid treatment.
- Published in:
- Liver International, 2017, v. 37, n. 11, p. 1743, doi. 10.1111/liv.13567
- By:
- Publication type:
- Article
Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection.
- Published in:
- Liver International, 2017, v. 37, n. 1, p. 5, doi. 10.1111/liv.13212
- By:
- Publication type:
- Article
Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real‐world cohorts.
- Published in:
- Journal of Viral Hepatitis, 2022, v. 29, n. 12, p. 1050, doi. 10.1111/jvh.13738
- By:
- Publication type:
- Article
Effect of Different Interferonα2 Preparations on IP10 and ET-1 Release from Human Lung Cells.
- Published in:
- PLoS ONE, 2012, v. 7, n. 10, p. 1, doi. 10.1371/journal.pone.0046779
- By:
- Publication type:
- Article
HEPLA: A multicenter study on demographic and disease characteristics of patients with hepatitis C in Latin America.
- Published in:
- Annals of Hepatology: Official Journal of the Mexican Association of Hepatology, 2020, v. 19, n. 2, p. 161, doi. 10.1016/j.aohep.2019.09.006
- By:
- Publication type:
- Article
SVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHESYS study.
- Published in:
- Annals of Hepatology: Official Journal of the Mexican Association of Hepatology, 2014, v. 13, n. 2, p. 303, doi. 10.1016/s1665-2681(19)30896-8
- By:
- Publication type:
- Article
A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin.
- Published in:
- Liver International, 2014, v. 34, n. 10, p. 1550, doi. 10.1111/liv.12439
- By:
- Publication type:
- Article
In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions.
- Published in:
- Liver International, 2014, v. 34, n. 7, p. e217, doi. 10.1111/liv.12352
- By:
- Publication type:
- Article
Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients.
- Published in:
- Liver International, 2012, v. 32, n. 8, p. 1270, doi. 10.1111/j.1478-3231.2012.02819.x
- By:
- Publication type:
- Article